Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Large Volume Parenteral (LVP) share of total revenue % ・Standalone data |
|
||||||||||
| Manufactured goods share of total revenue % ・Standalone data |
|||||||||||
| Domestic (India) sales share of total revenue % ・Standalone data |
|||||||||||
| Permanent employees on rolls count ・Standalone data |
|||||||||||
| R&D expenditure as % of total turnover % ・Standalone data |
|||||||||||
| Number of stockists (CFA) pan-India count ・Standalone data |
|||||||||||
| Placentrex (flagship brand) share of revenue % ・Standalone data |
|||||||||||
| Top 5 customers share of net sales % ・Standalone data |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Submitted minutes of 87th AGM held on 6 August 2026 via VC/OAVM.
-
Voting Results For The 87Th Annual General Meeting Of The Company.
- 87th AGM voting results: all 7 resolutions passed, including Rs.5 dividend and CEO appointment.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication regarding extract of unaudited financial results for the first quarter ended 30th June, 2026
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- 87th AGM on 6 Aug 2026 approved Rs5 dividend and appointed Amit Mahla as WTD & CEO for 5 years.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.